Earlier this week, renowned Mexican physician, Dr. Saul Garza Morales held a conference in Mexico City to report the findings from his study of children suffering from Lennox-Gastaut Syndrome. The report found that children who suffer from this severe form of epilepsy and were treated with Real Scientific Hemp Oil-X (RSHO-X,) responded positively to the treatment making this a promising advancement in medicine. RSHO-X can be prescribed by a doctor for any condition, disease or disorder and is distributed by Hemp Meds Mexico, the first company approved for medical cannabis products to be imported into the country. As it stands, Hemp Meds has helped over 260 children.
Between 2016 and 2017, Dr. Garza tested 39 patients who were given five to seven milligrams CBD/kg of RSHO-X in progressive doses depending on their weight. The results were positive, they found that 84 percent of patients saw a reduction in motor seizures. Fifty-three percent saw a better than 75 percent reduction in seizures. Seventeen percent saw a full elimination of seizures all together over a four-month period. And finally 100 percent of patients reported zero side effects. These results are remarkable considering the severity of Lennox-Gastaut Syndrome.
LGS is a rare and very severe form of epilepsy that typically develops early in children with the average age between two and eight years.
LGS is very difficult to treat due to the patients suffering from many different kinds of seizures, including atonic and tonic, at many different frequencies. With 30,000 people in the United States and 300,000 people worldwide born with this condition, finding a lasting form of treatment was imperative. In the past, children who suffer from LGS were given limited options as once the disorder reaches the drug resistant phase, no further treatment is available. In addition to the debilitating seizures, children can also experience learning difficulties, developmental delays and behavioral problems.
Dr. Stuart Titus, Chief Executive Officer of Medical Marijuana, Inc. shared his excitement with Dr. Garza’s breakthrough discovery saying, “The results of this study are very exciting as they show the best results of any product/medication ever recorded regarding the reduction of seizures in Lennox-Gastaut patients . . . ”
These types of studies are vital, not only for improving the quality of life for thousands of children around the world, but also for the development of cannabis and the numerous benefits it provides throughout the medical field.
Dr. Garza, who has 25 years of experience specializing in Pediatric Neurology, Epilepsy and learning disabilities is now setting his sights on a new study that examines the effects of CBD and autism.